5-lipoxygenase pathway in experimental abdominal aortic aneurysms

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 12, 2014, Pages 2669-2678

  Bhamidipati, Castigliano M ^a   Whatling, Carl A ^d,e   Mehta, Gaurav S ^b,d   Meher, Akshaya K ^a   Hajzus, Vanessa A ^a   Su, Gang ^c   Salmon, Morgan ^b   Upchurch, Gilbert R ^c,d   Owens, Gary K ^d   Ailawadi, Gorav ^a,b,d  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b Department of Surgery ^*

^c McLaren Bay Region   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

Aneurysm; Aorta, abdominal; Arachidonate 5 lipoxygenase; Inflammation; Leukotriene B4 .

Indexed keywords

ALPHA ACTIN; ANGIOTENSIN II; ARACHIDONATE 5 LIPOXYGENASE; CASPASE 3; ELASTASE; GELATINASE B; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ALOX5 PROTEIN, HUMAN; LIPOXYGENASE INHIBITOR; MMP9 PROTEIN, MOUSE; PANCREATIC ELASTASE;

ABDOMINAL AORTA ANEURYSM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; ABDOMINAL AORTA; AGED; ANIMAL; AORTIC ANEURYSM, ABDOMINAL; BIOSYNTHESIS; BONE MARROW TRANSPLANTATION; C57BL MOUSE; COMPLICATION; DEFICIENCY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HISTOCOMPATIBILITY; HUMAN; HYPERCHOLESTEROLEMIA; KNOCKOUT MOUSE; MALE; METABOLISM; MIDDLE AGED; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; SIGNAL TRANSDUCTION;

AGED; ANGIOTENSIN II; ANIMALS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; ARACHIDONATE 5-LIPOXYGENASE; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; HYPERCHOLESTEROLEMIA; LIPOXYGENASE INHIBITORS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; NEUTROPHIL INFILTRATION; PANCREATIC ELASTASE; RECEPTORS, LDL; SIGNAL TRANSDUCTION; TRANSPLANTATION CHIMERA;

EID: 84918779251     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304016     Document Type: Article

References (39)

1. (WISQARS™) CDC. 20 leading causes of death, United States. Injury Prevention & Control: Data & Statistics. 2007. http://www.cdc.gov/injury/wisqars/leadingcauses.html. Accessed September 15, 2014.
2. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Natl Vital Stat Rep. 2013;61:1-117.
3. Thompson RW, Curci JA, Ennis TL, Mao D, Pagano MB, Pham CT. Pathophysiology of abdominal aortic aneurysms: insights from the elastase-induced model in mice with different genetic backgrounds. Ann N Y Acad Sci. 2006;1085:59-73.
4. Ailawadi G, Eliason JL, Upchurch GR Jr. Current concepts in the pathogenesis of abdominal aortic aneurysm. J Vasc Surg. 2003;38:584-588.
5. Prall AK, Longo GM, Mayhan WG, Waltke EA, Fleckten B, Thompson RW, Baxter BT. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg. 2002;35:923-929.
6. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294:1871-1875.
7. Funk CD, Cao RY, Zhao L, Habenicht AJ. Is there a role for the macrophage 5-lipoxygenase pathway in aortic aneurysm development in apolipoprotein E-deficient mice? Ann N Y Acad Sci. 2006;1085:151-160.
8. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol. 2007;50:470-479.
9. Poeckel D, Funk CD. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc Res. 2010;86:243-253.
10. Di Gennaro A, Wågsäter D, Mäyränpää MI, Gabrielsen A, Swedenborg J, Hamsten A, Samuelsson B, Eriksson P, Haeggström JZ. Increased expression of leukotriene C4 synthase and predominant formation of cysteinylleukotrienes in human abdominal aortic aneurysm. Proc Natl Acad Sci USA. 2010;107:21093-21097.
11. Rådmark O, Samuelsson B. Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. Biochem Biophys Res Commun. 2010;396:105-110.
12. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov. 2005;4:664-672.
13. Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol. 2008;9:162-176.
14. Zhao L, Moos MP, Gräbner R, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med. 2004;10:966-973.
15. Ahluwalia N, Lin AY, Tager AM, Pruitt IE, Anderson TJ, Kristo F, Shen D, Cruz AR, Aikawa M, Luster AD, Gerszten RE. Inhibited aortic aneurysm formation in BLT1-deficient mice. J Immunol. 2007;179:691-697.
16. Kristo F, Hardy GJ, Anderson TJ, Sinha S, Ahluwalia N, Lin AY, Passeri J, Scherrer-Crosbie M, Gerszten RE. Pharmacological inhibition of BLT1 diminishes early abdominal aneurysm formation. Atherosclerosis. 2010;210:107-113.
17. Houard X, Ollivier V, Louedec L, Michel JB, Bäck M. Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus. FASEB J. 2009;23:1376-1383.
18. Houard X, Touat Z, Ollivier V, Louedec L, Philippe M, Sebbag U, Meilhac O, Rossignol P, Michel JB. Mediators of neutrophil recruitment in human abdominal aortic aneurysms. Cardiovasc Res. 2009;82:532-541.
19. Bisoendial RJ, Tanck MW, Golledge J, Broekhuizen LN, Legemate D.A., Stroes ES, Norman PE. The association between the gene encoding 5-lipoxygenase activating protein and abdominal aortic aneurysms. Atherosclerosis. 2012;220:425-428.
20. Cao RY, Adams M.A., Habenicht AJ, Funk CD. Angiotensin II-induced abdominal aortic aneurysm occurs independently of the 5-lipoxygenase pathway in apolipoprotein E-deficient mice. Prostaglandins Other Lipid Mediat. 2007;84:34-42.
21. Whatling C, McPheat W, Herslöf M. The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field. Expert Opin Investig Drugs. 2007;16:1879-1893.
22. Daugherty A, Cassis L. Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor-/-mice. Ann N Y Acad Sci. 1999;892:108-118.
23. Daugherty A, Manning MW, Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605-1612.
24. Daugherty A, Cassis L.A. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2004;24:429-434.
25. Daugherty A, Cassis L. Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc Med. 2004;14:117-120.
26. Serhan CN. Resolution phase of inflammation: novel endogenous antiinflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101-137.
27. Fischer L, Szellas D, Rådmark O, Steinhilber D, Werz O. Phosphorylationand stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J. 2003;17:949-951.
28. Werz O, Szellas D, Henseler M, Steinhilber D. Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Mol Pharmacol. 1998;54:445-451.
29. Brock TG, Maydanski E, McNish RW, Peters-Golden M. Co-localization of leukotriene a4 hydrolase with 5-lipoxygenase in nuclei of alveolar macrophages and rat basophilic leukemia cells but not neutrophils. J Biol Chem. 2001;276:35071-35077.
30. Folkesson M, Kazi M, Zhu C, Silveira A, Hemdahl AL, Hamsten A, Hedin U, Swedenborg J, Eriksson P. Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurysms. Thromb Haemost. 2007;98:427-433.
31. Fontaine V, Touat Z, Mtairag el M, Vranckx R, Louedec L, Houard X, Andreassian B, Sebbag U, Palombi T, Jacob MP, Meilhac O, Michel JB. Role of leukocyte elastase in preventing cellular re-colonization of the mural thrombus. Am J Pathol. 2004;164:2077-2087.
32. Hannawa KK, Eliason JL, Woodrum DT, Pearce CG, Roelofs KJ, Grigoryants V, Eagleton MJ, Henke PK, Wakefield TW, Myers DD, Stanley JC, Upchurch GR Jr. L-selectin-mediated neutrophil recruitment in experimental rodent aneurysm formation. Circulation. 2005;112:241-247.
33. Eliason JL, Hannawa KK, Ailawadi G, Sinha I, Ford JW, Deogracias MP, Roelofs KJ, Woodrum DT, Ennis TL, Henke PK, Stanley JC, Thompson RW, Upchurch GR Jr. Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation. Circulation. 2005;112:232-240.
34. Grigoryants V, Hannawa KK, Pearce CG, Sinha I, Roelofs KJ, Ailawadi G, Deatrick KB, Woodrum DT, Cho BS, Henke PK, Stanley JC, Eagleton MJ, Upchurch GR. Tamoxifen up-regulates catalase production, inhibits vessel wall neutrophil infiltration, and attenuates development of experimental abdominal aortic aneurysms. J Vasc Surg. 2005;41:108-114.
35. Sinha I, Cho BS, Roelofs KJ, Stanley JC, Henke PK, Upchurch GR Jr. Female gender attenuates cytokine and chemokine expression and leukocyte recruitment in experimental rodent abdominal aortic aneurysms. Ann N Y Acad Sci. 2006;1085:367-379.
36. Shi GP. Role of cathepsin C in elastase-induced mouse abdominal aortic aneurysms. Future Cardiol. 2007;3:591-593.
37. Pagano MB, Zhou HF, Ennis TL, Wu X, Lambris JD, Atkinson JP, Thompson RW, Hourcade D.E., Pham CT. Complement-dependent neutrophil recruitment is critical for the development of elastase-induced abdominal aortic aneurysm. Circulation. 2009;119:1805-1813.
38. Pétrin D, Turcotte S, Gilbert AK, Rola-Pleszczynski M, Stankova J. The anti-apoptotic effect of leukotriene B4 in neutrophils: a role for phosphatidylinositol 3-kinase, extracellular signal-regulated kinase and Mcl-1. Cell Signal. 2006;18:479-487.
39. Samson R. Can pharmacologic agents slow abdominal aortic aneurysm growth? Semin Vasc Surg. 2012;25:25-28.